Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
25 janv. 2023 07h00 HE
|
Cidara Therapeutics, Inc.
FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive candidiasis in over a decade ...
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
04 janv. 2023 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
01 déc. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split
29 nov. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet
28 nov. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
Publication details the efficacy and safety of rezafungin dosed once-weekly versus the current of care dosed once-daily Rezafungin PDUFA target action date is scheduled for March 22, 2023 SAN DIEGO...
Cidara Therapeutics to Participate in the World Antiviral Congress 2022
23 nov. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics to Present at the Stifel Healthcare Conference
08 nov. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
03 nov. 2022 17h47 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for...
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
17 oct. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
04 oct. 2022 08h00 HE
|
Cidara Therapeutics, Inc.
Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin Company eligible to receive up to an additional $108M in milestones from...